Eli Lilly’s juggernaut diabetes and obesity drugs Mounjaro and Zepbound have been erased from the FDA’s shortage list, ...

Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer's disease, ALS and other brain ...

Eli Lilly's tirzepatide, sold as Zepbound for weight loss and Mounjaro to treat diabetes, has been in short supply since 2022 amid skyrocketing demand. The medication is part of the blockbuster ...

Lilly's long-term growth prospects make the stock a great pick. Much of this success is due to two products, Mounjaro and Zepbound, which are the same drug marketed under different brands for ...

In Q2, it brought in $11.3 billion in sales, 36% higher than a year prior, and it cranked up its annual revenue guidance for ...

Eli Lilly (NYSE:LLY) investing $4.5B to create Lilly Med Foundry, with goal of faster drug pipeline and scaling molecules to medicines. Stock outlook mixed.

Diabetes drug Mountjaro has been on the list since 2022 and weight-loss drug Zepbound was added in April. The shortage has forced consumers to turn to drug compounders, who make equivalent ...

To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.

Eli Lilly is on the verge of becoming the world's first pharmaceutical company to reach a market value of $1 trillion. This ...

Eli Lilly (NYSE: LLY) and Novo Nordisk (NYSE: NVO) are archrivals thanks to their dueling drugs for weight loss, Zepbound and ...

Much of this success is due to two products, Mounjaro and Zepbound, which are the same drug marketed under different brands for treating type 2 diabetes and obesity, respectively. But Mounjaro and ...